The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma.
J. F. De Groot
No relevant relationships to disclose
T. Cloughesy
No relevant relationships to disclose
F. S. Lieberman
No relevant relationships to disclose
S. M. Chang
No relevant relationships to disclose
A. M. P. Omuro
No relevant relationships to disclose
J. Drappatz
No relevant relationships to disclose
T. Batchelor
No relevant relationships to disclose
L. M. DeAngelis
No relevant relationships to disclose
M. R. Gilbert
No relevant relationships to disclose
W. K. A. Yung
No relevant relationships to disclose
J. D. Fisher
No relevant relationships to disclose
X. Ye
No relevant relationships to disclose
K. Lamborn
No relevant relationships to disclose
A. P. Chen
No relevant relationships to disclose
S. A. Grossman
No relevant relationships to disclose
M. Prados
No relevant relationships to disclose
P. Y. Wen
No relevant relationships to disclose